About Us

Pioneering the Future of Genetic Medicine: Sinuotides’ Strategic Vision

Our Foundation

Established in 2025, Sinuotides is a specialized biopharmaceutical enterprise at the forefront of small nucleic acid and therapeutic peptide innovation. We are driven by a singular mission: to bridge the gap between advanced biotechnology and patient accessibility by developing high-purity, transformative therapies for unmet global medical needs.

Our Scientific Commitment

Leveraging a vertically integrated model—from non-infringing process development to sophisticated sameness characterization—we ensure that every molecule we develop meets the highest standards of safety and efficacy. Our expertise in oligonucleotide synthesis and complex peptide chemistry allows us to deliver affordable, life-changing solutions without compromising on scientific rigor.

The Five-Year Roadmap

As we look toward 2030, our commitment is to rapidly scale our pipeline of Next-Generation Therapeutics. We aim to establish ourselves as a global leader in the specialized fields of RNA-based medicine and bioactive peptides, improving health outcomes through patient-centric innovation and strategic CDMO partnerships.

Our Purpose

Driven by passion and precision, Sinuotides strives to be a trusted pillar of the global healthcare ecosystem. We are not just developing drugs; we are empowering patients and shaping a healthier, more equitable future for all.

The Sinuotides Edge: A Vertically Integrated Ecosystem for Oligonucleotide Generics

Executive Summary

Sinuotides operates a highly specialized, vertically integrated model designed to eliminate the traditional bottlenecks in oligonucleotide generic development. By controlling every critical phase—from raw material sourcing and proprietary synthesis to clinical formulation and global regulatory filing—we achieve unmatched speed-to-market and cost-efficiency.

Core Operational Pillars

• Upstream Excellence (DS & IP): We initiate development by securing a robust raw material supply chain and optimizing solid-phase synthesis. Our focus on IP-compliant process engineering ensures that our synthetic routes are entirely "non-infringing," providing a clear, risk-free path to global commercialization.
• Analytical Rigor (Sameness): At the heart of our model is the Sameness & Characterization study. Utilizing cutting-edge analytics—including high-resolution LC-MS, NMR, and Circular Dichroism—we provide definitive proof that our molecules are chemically and structurally identical to the Reference Listed Drug (RLD).
• Downstream Scalability (DP & CMO): Our Drug Product team specializes in stabilizing sensitive oligonucleotides into high-quality injectable or lyophilized dosage forms. Through our strategic partnership with Asymchem, we scale these processes in GMP-certified facilities to produce the formal exhibition batches required for stability testing.
• Global Market Access: Our roadmap concludes with the compilation of a comprehensive Common Technical Document (CTD). This allows for seamless, multi-region submissions (ANDA/MAA) to the FDA, EMA, and other leading health authorities, ensuring patients worldwide receive affordable, life-changing therapies.